Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston
7
×
boston blog main
fda
7
×
life sciences
national blog main
boston top stories
clinical trials
deals
national top stories
san francisco blog main
alexion pharmaceuticals
biotech ipos
hepatitis b
investing
nonalcoholic steatohepatitis
rare disease drugs
roche
san francisco top stories
akouos
aligos therapeutics
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
astellas pharmaceuticals
autoimmune disorders
avapritinib
baker brothers life sciences
benzodiazepine
blackstone group
blepharitis
blueprint medicines
boehringer ingelheim
california institute for biomedical research
cavion
cephalgia
chronic hepatitis b virus
complement system
crispr
cstone pharmaceuticals
cystic fibrosis
What
medicines
7
×
drug
pharmaceuticals
candidate
developing
disease
fda
ipo
muscle
pharma
research
roche
team
therapeutics
affects
alternative
americans
approval
approved
autoimmune
biotechs
blueprint
brings
cancer
caught
causing
central
cf
cns
company
crisis
currently
cystic
date
deal
developer
dicerna
disorder
disorders
drugs
Language
unset
unknown
Current search:
fda
×
biotech
×
medicines
×
boston
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles